CD274
E1423944
UNEXPLORED
CD274, also known as PD-L1, is an immune checkpoint protein expressed on various cells that helps tumors evade immune detection and is a key target of several cancer immunotherapies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CD274 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T20301131 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CD274 Context triple: [Imfinzi, hasMolecularTarget, CD274]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
Nectin-4/CD137 (via BT7480)
Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
D.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
E.
CD340
CD340 is an alternative name for the human epidermal growth factor receptor 2 (HER2), a cell surface receptor tyrosine kinase often overexpressed in certain aggressive breast and gastric cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CD274 Target entity description: CD274, also known as PD-L1, is an immune checkpoint protein expressed on various cells that helps tumors evade immune detection and is a key target of several cancer immunotherapies.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
Nectin-4/CD137 (via BT7480)
Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
D.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
E.
CD340
CD340 is an alternative name for the human epidermal growth factor receptor 2 (HER2), a cell surface receptor tyrosine kinase often overexpressed in certain aggressive breast and gastric cancers.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.